ethyl-benzyl-pentyl-amine | 855271-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl-benzyl-pentyl-amine
• 英文别名: Aethyl-benzyl-pentyl-amin；N-benzyl-N-ethylpentan-1-amine
• CAS: 855271-19-1
• 化学式: C₁₄H₂₃N
• 分子量: 205.343
• InChiKey: KTPFRNPPJARMEA-UHFFFAOYSA-N

物化性质

• 沸点：
  117-121 °C(Press: 8 Torr)
• 密度：
  0.898±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ethyl-benzyl-pentyl-amine 在 溶剂黄146 、 铂 作用下， 65.0~75.0 ℃ 、294.17 kPa 条件下， 生成 N-乙基戊胺
  参考文献：
  名称：

  Buck; Baltzly, Journal of the American Chemical Society, 1941, vol. 63, p. 1965

  摘要：

  DOI：
• 作为产物：
  描述：

  溴乙烷 、 N-benzyl-N-pentylamine 在 乙醇 作用下， 生成 ethyl-benzyl-pentyl-amine
  参考文献：
  名称：

  Buck; Baltzly, Journal of the American Chemical Society, 1941, vol. 63, p. 1965

  摘要：

  DOI：

文献信息

• SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES
  申请人：ADAMED SP. Z O.O

  公开号：US20150051257A1

  公开（公告）日：2015-02-19

  Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted; or 9- or 10-membered bicyclic group, linked to —(O) x —(CH2) y — through one of its aromatic carbon atoms, consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5- or 6-membered non-aromatic heterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C 1 -C 3 -alkyls; D represents a group selected from: phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted; thiophene unsubstituted or substituted; bicyclic group consisting of imidazolering fused with 5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2 heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring; and bicyclic group consisting of benzene ring fused with—or 6-membered non-aromatic heterocyclic ring having 1 or 2 heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon N atoms of benzene ring; R represents H or —CH 3; x is 0 or 1; y is 2 or 3; and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents —CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

  苯甲胺的磺胺基衍生物，其化学式（I）中，A代表未取代或取代的苯基；或与—(O)x—(CH2)y—连接的9-或10-成员双环族，通过其芳香碳原子之一，由与含1或2个异原子（N和O）中独立选择的群组成的芳香环并联的苯环构成，其中此类双环族未取代或取代，或者与含1或2个O原子的5-或6-成员非芳香杂环取代或未取代，其中杂环未取代或取代为一个或多个C1-C3-烷基；D代表选自：未取代或取代的苯基；未取代或取代的萘基；未取代或取代的噻吩基；由咪唑环并联的5-成员非芳香碳环组成的双环族；由苯环并联的含1或2个异原子（N、O和S）中独立选择的群组成的5-成员杂芳环，未取代或取代，并通过苯环的一个碳原子之一与磺胺基团连接；以及由苯环并联的含1或2个异原子（N和O）中独立选择的群组成的5-或6-成员非芳香杂环取代或未取代，并通过苯环的一个碳N原子之一与磺胺基团连接；R代表H或—CH3；x为0或1；y为2或3；以及其药学上可接受的盐和溶剂合物，但如果x为0且y为2，则D为未取代或取代的萘基，且如果R代表—CH3，则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
• [EN] SULPHONAMIDE DERIVATIVES OF BENZYLAMINE FOR THE TREATMENT OF CNS DISEASES<br/>[FR] DÉRIVÉS DE SULFONAMIDE DE LA BENZYLAMINE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL (SNC)
  申请人：ADAMED SP ZOO

  公开号：WO2013140347A1

  公开（公告）日：2013-09-26

  Sulphonamide derivatives of benzylamine of formula (I), wherein A represents phenyl unsubstituted or substituted;or 9-or 10-membered bicyclic group, linked to –(O) x - (CH 2 ) y -through one of its aromatic carbon atoms,consisting of benzene ring fused with -membered heteroaromatic ring containing 1 or 2 heteroatoms independently selected from the group consisting of N and O, wherein such bicyclic group is unsubstituted or substituted or with 5-or 6-membered non-aromaticheterocyclic ring having 1 or 2 O atoms, wherein heterocyclic ring is unsubstituted or substituted with one or more C1 -C3 - alkyls; D represents a group selected from:phenyl unsubstituted or substituted; naphthyl unsubstituted or substituted;thiophene unsubstituted or substituted;bicyclic group consisting of imidazolering fused with5-membered non-aromatic carbocyclic ring; bicyclic group consisting of benzene ring fused with 5-membered heteroaromatic ring, having 1 or 2heteroatoms independently selected from the group consisting of N, O and S, unsubstituted or substituted and linked to sulphonamide moiety through one of carbon atoms of benzene ring;and bicyclic group consisting of benzene ring fused with -or 6-membered non-aromatic heterocyclic ring having 1 or 2heteroatoms independently selected from the group consisting of N and O, unsubstituted or substituted, and linked to sulphonamide moiety through one of carbon atoms of benzene ring;R represents H or –CH 3;x is 0 or 1;yis 2 or 3;and pharmaceutically acceptable salts and solvates thereof, with the provisos that if x is 0 and y is 2, then D is naphthyl unsubstituted or substituted with one halogen atom, and if R represents –CH 3, then A is not unsubstituted or substituted phenyl. The compounds can be used in the treatment and/or prophylaxis of central nervous system disorders.

  苯甲胺的磺胺基衍生物的化学式（I），其中A代表未取代或取代的苯基；或9-或10-成员的双环族，通过其中一个芳香碳原子连接到-(O) x - (CH 2 ) y -，由苯环与含有1个或2个杂原子（从N和O组成的组中独立选择）的-成员杂芳环融合而成，其中该双环族未取代或取代，或与含有1个或2个O原子的5-或6-成员非芳杂环取代，其中杂环未取代或取代为一个或多个C1 -C3 -烷基；D代表从中选择的一组：未取代或取代的苯基；未取代或取代的萘基；未取代或取代的噻吩基；由咪唑环融合而成的5-成员非芳碳环的双环族；由苯环融合而成的含有1个或2个杂原子（从N、O和S组成的组中独立选择）的5-成员杂芳环的双环族，未取代或取代，并通过苯环的一个碳原子与磺胺基团连接；以及由苯环融合而成的5-或6-成员非芳杂环的双环族，其中杂原子独立选择自N和O组成的组，未取代或取代，并通过苯环的一个碳原子与磺胺基团连接；R代表H或-CH 3；x为0或1；y为2或3；以及其药学上可接受的盐和溶剂化合物，但是如果x为0且y为2，则D为未取代或取代的萘基且带有一个卤原子，如果R代表-CH 3，则A不是未取代或取代的苯基。这些化合物可用于治疗和/或预防中枢神经系统疾病。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• MULTI-RING COMPOUNDS AND USES THEREOF
  申请人：Ohler Norman E.

  公开号：US20100249111A1

  公开（公告）日：2010-09-30

  Chemical agents, such as derivatives of hydroxy benzene moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

  本发明涉及化学制剂，例如羟基苯基衍生物及类似的杂环环结构，包括其盐，其作为抗癌和抗肿瘤制剂，特别是这些制剂调节细胞中的酶和结构多肽的活性，例如癌细胞，或这些制剂调节细胞系统中的基因表达水平，包括癌细胞等。本发明还涉及制备这些制剂的方法，以及包含这些制剂作为活性成分的制药组合物和使用这些制剂作为治疗剂的方法。
• 3-Substituted-6-Aryl Pyridines
  申请人：Hutchison Alan J.

  公开号：US20090176980A1

  公开（公告）日：2009-07-09

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I中的3-取代-6-芳基吡啶化合物： 其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及在治疗各种炎症，心血管和免疫系统疾病中使用这些化合物的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体的定位探针。